TABLE 1.
Features of suspected PML patients and controlsa
| Variable | Suspected PML (n = 59) |
Controls (n = 224) | |
|---|---|---|---|
| Pre-HAART era (n = 19) | HAART era (n = 40) | ||
| Mean age (yr) ± SD | 38 ± 7 | 39 ± 7 | 37 ± 7 |
| Sex (% female) | 10.5 | 20.0 | 26.8 |
| IDU (%) | 68.4 | 52.5 | 50.0 |
| Prior CDC class C (%) | 36.8 | 50.0 | 41.5 |
| CD4 (mean no. of cells/μl ± SD) | 51 ± 49 | 104 ± 134 | 48 ± 55 |
| Plasma HIV RNA median (IQR) (95% CI) (only for HAART era) | ND | 4.78 (3.47-5.53) | 5.14 (4.23-5.66) |
| NRTI therapy at onset (%) | 57.9 | 0 | 14.6 |
| HAART at onset (%) | 0 | 42.5 | 39.0 |
a
Suspected PML was defined by the concomitant presence of compatible clinical and brain magnetic resonance imaging features, the exclusion of alternative diagnoses by PCR assays in the CSF, and clinical follow-up (1, 8). IDU, intravenous drug user; CDC, Centers for Disease Control; IQR, interquartile range; NRTI, nucleoside reverse transcriptase inhibitor; ND, not detected.